IVERIC BIO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 163
- Market Cap
- -
- Website
- http://www.ivericbio.com
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
Phase 2
Terminated
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- IVERIC bio, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05571267
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
Phase 3
Completed
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Drug: Sham
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- IVERIC bio, Inc.
- Target Recruit Count
- 448
- Registration Number
- NCT04435366
- Locations
- 🇺🇸
Jules Stein Eye Institute/David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Retina and Vitreous of Texas, PLLC, Houston, Texas, United States
🇺🇸Cincinnati Eye Institute, Cincinnati, Ohio, United States
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Phase 2
Completed
- Conditions
- Geographic AtrophyDry Age-Related Macular Degeneration
- Interventions
- Other: Sham
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- IVERIC bio, Inc.
- Target Recruit Count
- 286
- Registration Number
- NCT02686658
- Locations
- 🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Czechia
🇨🇿Fakultni Nemocnice Brno, Brno, Czechia
🇨🇿Faculty Hospital Hradec Kralove, Hradec Králové, Czechia
© Copyright 2025. All Rights Reserved by MedPath